Sarepta Therapeutics
SRPT
330 hedge funds and large institutions have $5.04B invested in Sarepta Therapeutics in 2021 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 101 increasing their positions, 129 reducing their positions, and 87 closing their positions.
1% more capital invested
Capital invested by funds: $4.97B → $5.04B (+$74.3M)
2% less call options, than puts
Call options by funds: $97M | Put options by funds: $98.8M
2.47% less ownership
Funds ownership: 83.79% → 81.32% (-2.5%)
10% less funds holding
Funds holding: 366 → 330 (-36)
22% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 129
37% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$196M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$54.8M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$46.7M |
| 4 |
JP Morgan Chase
New York
|
+$41.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$35.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$248M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$103M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$52M |
| 4 |
BlackRock
New York
|
-$49.1M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$31.5M |
SRPT Hedge Fund Activity: Q2 2021 in Review
330 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2021, worth a combined $5.04B — up 1.5% from $4.97B a quarter earlier.
Sellers outnumbered buyers: 87 funds closed out of SRPT and 55 opened new positions — a net loss of 32 holders — while 129 trimmed existing stakes and 101 added.
The largest buyer was Sands Capital Management, adding an estimated $196M. The largest seller was Capital Research Global Investors, cutting an estimated $248M.
- 330 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2021, down from 366 in Q1 2021.
- Funds reported $5.04B of Sarepta Therapeutics stock for Q2 2021, up 1.5% quarter-over-quarter.
- 55 funds opened new Sarepta Therapeutics positions in Q2 2021 and 87 closed out, a net change of -32 holders.
- The largest Sarepta Therapeutics buyer in Q2 2021 was Sands Capital Management, an estimated $196M added.
- The largest Sarepta Therapeutics seller in Q2 2021 was Capital Research Global Investors, an estimated $248M sold.
Based on aggregated 13F filings for Q2 2021.